High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 1, 2013, Pages 131-139

  Schindewolf, Marc ^a   Gobst, Corinna ^a   Kroll, Hartmut ^b   Recke, Andreas ^c   Louwen, Frank ^a   Wolter, Manfred ^a   Kaufmann, Roland ^a   Boehncke, Wolf Henning ^a,d   Lindhoff Last, Edelgard ^a   Ludwig, Ralf J ^a,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Institute for Transfusion Medicine Dessau   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Allergy; Delayed type hypersensitivity reaction; Heparin; Heparin induced thrombocytopenia; Low molecular weight heparin; Pregnancy; Skin

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ADULT; ALLERGIC REACTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CROSS REACTION; DEEP VEIN THROMBOSIS; DELAYED HYPERSENSITIVITY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HAZARD RATIO; HEART ATRIUM FLUTTER; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PREGNANCY; HUMAN; INCIDENCE; LOCAL SKIN REACTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MECHANICAL HEART VALVE; PERIPHERAL VEIN; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; SECOND TRIMESTER PREGNANCY; SKIN BIOPSY; SKIN MANIFESTATION; THIRD TRIMESTER PREGNANCY; THROMBOSIS;

EID: 84882832922     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.02.047     Document Type: Article

References (44)

1. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e691S-736S.
2. Schindewolf M, Schwaner S, Wolter M, Kroll H, Recke A, Kaufmann R, et al. Incidence and causes of heparin-induced skin lesions. CMAJ 2009;181:477-81.
3. Schindewolf M, Ludwig RJ, Wolter M, Hardt K, Kaufmann R, Lindhoff-Last E, et al. Diagnosis of heparin-induced delayed-type hypersensitivity. Phlebologie 2010;39:226-31.
4. Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet 2012;380:1867-79.
5. Schindewolf M, Kroll H, Ackermann H, Garbaraviciene J, Kaufmann R, Boehncke WH, et al. Heparin-induced skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010;8:1486-91.
6. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005;127:1857-61.
7. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 2006;96:611-7.
8. Schindewolf M, Magnani HN, Lindhoff-Last E. Danaparoid in pregnancy in cases of heparin intolerance-use in 59 cases. Haemostaseologie 2007;27:89-97.
9. Bank I, Libourel EJ, Middeldorp S, Van Der Meer J, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost 2003;1:859-61.
10. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362:1586-96.
11. Deruelle P, Denervaud M, Hachulla E, Ducloy-Bouthors AS, Valat AS, Puech F, et al. Use of low-molecular-weight heparin from the first trimester of pregnancy: a retrospective study of 111 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006;127:73-8.
12. Baglin TP. Low-molecular-weight heparins and new strategies for the treatment of patients with established venous thrombosis. Haemostasis 1996;26(suppl 2):10-5.
13. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warken-tin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 3rd ed. New York: Marcel Dekker; 2004. pp. 53-106.
14. Peitsch WK, Glorer E, Dempfle CE, Back W, Bayerl C, Goerdt S. Cutaneous necroses mainly on the extremities. Hautarzt 2004;55:410-3.
15. Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995;345:1326-30.
16. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65.
17. Eichler P, Budde U, Haas S, Kroll H, Loreth RM, Meyer O, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999;81:625-9.
18. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854-63.
19. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
20. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202-4.
21. Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study. Dermatol Surg 2001; 27:47-52.
22. Schellong SM, Schwarz T, Halbritter K, Beyer J, Siegert G, Oettler W, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 2003;89:228-34.
23. Harenberg J, Huhle G, Wang L, Hoffmann U, Bayerl C, Kerowgan M. Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Allergy 1999;54:473-7.
24. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996;92:494-7.
25. Fausett MB, Vogtlander M, Lee RM, Esplin MS, Branch DW, Rodgers GM, et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001;185:148-52.
26. Harrison SJ, Rafferty I, McColl MD. Management of heparin allergy during pregnancy with danaparoid. Blood Coagul Fibrinolysis 2001;12:157-9.
27. Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005;93:63-9.
28. Utikal J, Peitsch WK, Booken D, Velten F, Dempfle CE, Goerdt S, et al. Hypersen-sitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 2005;94:895-6.
29. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost 2005;94:1265-9.
30. Trautmann A, Hamm K, Bröcker E-B, Klein CE. Delayed hypersensitivity to hep-arins. Z Hautkr 1997;72:447-50.
31. Koch P, Munssinger T, Rupp-John C, Uhl K. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight hepa-rins: tolerance of a new recombinant hirudin. J Am Acad Dermatol 2000;42:612-9.
32. Schindewolf M, Scheuermann J, Kroll H, Garbaraviciene J, Hecking C, Marzi I, et al. Low allergenic potential with fondaparinux: results of a prospective investigation. Mayo Clin Proc 2010;85:913-9.
33. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul Fibrinolysis 2006;17:605-13.
34. van Boeckel CA, Petitou M. The unique antithrombin III binding domain of hep-arin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl 1993;32: 1671-90.
35. Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, et al. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol 2006;22:234-41.
36. Carreras E, Turner S, Frank MB, Knowlton N, Osban J, Centola M, et al. Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4. Blood 2010;115:238-46.
37. Mjosberg J, Svensson J, Johansson E, Hellstrom L, Casas R, Jenmalm MC, et al. Systemic reduction of functionally suppressive CD4dimCD25highFoxp31 Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estra-diol. J Immunol 2009;183:759-69.
38. Ludwig RJ, Beier C, Lindhoff-Last E, Kaufmann R, Boehncke WH. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 2003;49:158-9.
39. Harr T, Scherer K, Tsakiris DA, Bircher AJ. Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy 2006;61:787-8.
40. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux-data on efficacy and safety in special situations. Thromb Res 2012;129:407-17.
41. Patriarca G, Rossi M, Schiavino D, Schinco G, Fais G, Varano C, et al. Rush de-sensitization in heparin hypersensitivity: a case report. Allergy 1994;49:292-4.
42. Dave S, Park MA. Successful heparin desensitization: a case report and review of the literature. J Card Surg 2008;23:394-7.
43. al-Eryani AY, al-Momen AK, Fayed DF, Allam AK. Successful heparin desensitiz-ation after heparin-induced anaphylactic shock. Thromb Res 1995;79:523-6.
44. Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractio-nated heparins induce a downregulation of inflammation: decreased levels of proin-flammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006;133:62-7.